Annals of the Rheumatic Diseases 2008;67:942-948
EXTENDED REPORTS
Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis
1 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
2 Faculty of Medicine, University of Oslo, Norway
3 Department of Rheumatology, Martina Hansens Hospital, Sandvika, Norway
4 CombinatoRx Inc., Cambridge, Massachusetts, USA
5 Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
6 Department of Rheumatology, Østfold Hospital, Sarpsborg, Norway
Professor T K Kvien, Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N-0319 Oslo, Norway; t.k.kvien{at}medisin.uio.no
Objective: The novel synergistic drug candidate CRx-102 comprises dipyridamole and low dose prednisolone and is in clinical development for the treatment of immunoinflammatory diseases. The purpose of this clinical study was to examine the efficacy and safety of CRx-102 in patients with hand osteoarthritis (HOA).
Methods: The study was conducted as a blinded, randomised, placebo-controlled trial at four centres in Norway. Eligibility criteria included being of age 30–70 years, at least one swollen and tender joint, a Kellgren–Lawrence (K–L) score of 2 or higher on radiographs, and a score of at least 30 mm pain on the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) visual analogue pain scale (VAS). The primary endpoint was a reduction in pain from baseline to day 42 on the AUSCAN pain subscale. Two-sided p values for the differences in least squares (LS) means adjusted for baseline are presented.
Results: The mean age of the 83 patients with HOA was 60 years and 93% were females. CRx-102 was statistically superior to placebo at 42 days for changes in AUSCAN pain (LS mean –14.2 vs –4.0) and for clinically relevant secondary endpoints (joint pain VAS (–18.6 vs –6.3), patient global VAS (–15.9 vs –4.2)) in the intention to treat population. The most frequently reported adverse event during the study was headache (52% in CRx-102 vs 15% in the placebo group).
Conclusions: The novel synergistic drug candidate CRx-102 demonstrated efficacy by statistically reducing pain compared to placebo in HOA and was generally well tolerated.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
ard.2007.074401v1
67/7/942 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Pain (neurology)
-
Degenerative joint disease
-
Musculoskeletal syndromes
-
Osteoarthritis
-
Immunology (including allergy)
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
